Beating the Winter Blues: Seasonal Affective Disorder Therapeutics Market Poised to Exceed US$ 1.1 Billion by 2028

The global Seasonal Affective Disorder (SAD) Therapeutics market demnad is poised for substantial growth, with a projected valuation close to US$ 1.1 Billion by the end of 2028. Seasonal Affective Disorder, commonly known as winter depression, is a mood disorder that affects individuals during specific seasons, typically in the winter months when daylight is limited.

The prevalence of Seasonal Affective Disorder has been on the rise, driving the demand for effective therapeutics to manage the symptoms and improve patient’s quality of life. Factors such as changing lifestyles, increased awareness, and better diagnosis have contributed to the growth of the SAD Therapeutics market.

It has been noted that physicians across the globe are increasingly recommending Bright Light Therapy (BLT) as a prophylactic measure for Depression and Seasonal Affective Disorder Therapeutics. BLT provides a robust, rapid and completely anti-depressant effect. The light therapy onset should be typically within four days of Seasonal Affective Disorder. Monitoring should be done on a phase resetting basis on timed effects of the introduction of bright light.

The seasonal affective disorder (SAD) therapeutics market is pegged at around US$ 450 million in 2019, with a modest Y-o-Y increase of 3.9% over 2018, according to a recent intelligence report by Future Market Insights. While drugs and devices collectively contribute to the consumption volume of seasonal affective disorder therapeutics, the latter will remain a major shareholder in the market. Towards the end of 2019, more than 3.4 million devices are likely to be sold globally, in seasonal affective disorder therapeutics market.

Popular drugs preferred in seasonal affective disorder therapeutics include selective serotonin reuptake inhibitors (SSRIs), according to the report. While generics and branded drugs are widely available in seasonal affective disorder therapeutics market, Buproban and Citalopram continue to register relatively higher sales. FMI attributes this dominance to high availability of generic versions of the aforementioned drugs.

Download a sample to obtain additional highlights and key points on various market segments and their impact in the coming years @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8821

Bright light therapy that has been the most preferred line of treatment in seasonal affective disorder therapeutics continues to receive strong support from physicians and patients owing to positive end results. While more than half the sales of devices used in seasonal affective disorder therapeutics is accounted by light boxes, sales of desk lamps are also thriving at a brisk rate.

A highly recommended prophylactic measure involved in seasonal affective disorder therapeutics, light therapy is characterized by its rapid, reliable, and highly anti-depressant action. Extensive adoption of bright light therapy by the patients afflicted by a sub-syndromal disease and self-reporting patient population prompts at bolstered revenue visibility prospected for seasonal affective disorder treatment therapeutics in coming years.

key players

• Allergan plc.,
• Eli Lily Company,
• GlaxoSmithKline plc,
• Pfizer Inc.,
• Teva Pharmaceuticals Inc.,
• Bausch Health Companies Inc.,
• F. Hoffmann-La Roche AG, Mylan N.V.,
• Sanofi AG, Novartis AG,
• Janssen Pharmaceuticals, Inc.,
• The Sunbox Company,
• Verilux, Inc.,
• Carex Health,
• Northern Light Technologies,
• Beurer GmbH and Koninklijke Philips N.V.

Are you looking for customized information related to the latest trends, drivers, and challenges? Speak to Our Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-8821

Demand for Combination Therapy for SAD Picking Up

The report opines that light therapy is the first line of treatment that seasonal affective disorder therapeutics providers opt for. However, a possible ineffective outcome for certain patients of SAD related psychiatric illnesses and depression creates scope of combination therapies. Some of the recently reported clinical trials emphasize potential efficacy of combination of light therapy, psychotherapy, talk therapy, and antidepressants in seasonal affective disorder therapeutics.

Inaccessibility at workplaces or during traveling has been a shortfall of light box therapy over the years. To help patients suffering from SAD explore non-conventional alternatives to seasonal affective disorder therapeutics, Austria-based med-tech startup, Active Wearables, recently launched a wearable device – Pocket Sky – providing light therapy, practically anywhere. The wearable has a wireless charging feature and the battery life is claimed to last for a couple of weeks. The Pocket Sky will potentially serve as a portable and lightweight light therapy solution to patients of seasonal affective disorder. Such innovations will continue to innovate the seasonal affective disorder therapeutics market landscape.

Inadequate availability of research data and ineffective documentation, especially related to use of bright light and blue light in light therapy, is posing a long-term challenge to rapid revenue growth of seasonal affective disorder therapeutics market. Moreover, proven adversities associated with excessive use of antidepressants also remain a concern among physicians and patients alike, limiting healthy growth prospects of seasonal affective disorder therapeutics market.

The report tracks performance of global seasonal affective therapeutics market over 2018-2028. In-depth strategic profiles of some of the leading players have been covered in the report, including Allergan plc, Eli Lily Company, GlaxoSmithKline plc, Pfizer Inc., Teva Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Sanofi AG, Novartis AG, Janssen Pharmaceuticals, Inc., and Koninklijke Philips N.V. among others.

We Offer tailor-made Solutions to fit Your Requirements, Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-8821

Key Segment

based on treatment type

• light boxes
• dawn stimulators
• desk lamps
• sun visors

based on disorder type

• SSRIs
• SNRIs
• NDRIs
• TCAs
• MOAIs

based on Distribution channel

• institutional sales
• retail sales

based on regions

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania and MEA

Explore Wide-ranging Coverage of FMI’s Healthcare Landscape:

Antimicrobial Wound Care Dressings Market Sales: From 2023 to 2033, the global antimicrobial wound care dressings market is estimated to be worth US$ 1.38 billion, with a CAGR of 6.4%. The global antimicrobial wound dressings market is expected to reach US$ 2.57 billion by 2033.

Systemic Sclerosis Treatment Market Outlook: The global revenue from the systemic sclerosis treatment market stands at US$ 928.1 Million in 2022, with the global market expected to grow at a CAGR of 7.9% to reach a valuation of US$ 2.2 Billion by the end of 2033.

Osteotomy Plates Market Volume: The osteotomy plates market is forecasted to be appraised at US$ 615.5 million by 2033, up from US$ 375.5 million in 2023, advancing at a CAGR of 5.1% during the forecast period.

About Future Market Insights (FMI):

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10 years.

Contact Us:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
LinkedIn | Twitter | Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com